Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Enzymatica recruits Chief Financial Officer

Enzymatica AB
Posted on: 06 Sep 17

Press release
Lund, 6 September, 2017

Enzymatica recruits Chief Financial Officer

Enzymatica has recruited Therese Filmersson as its new Chief Financial Officer - CFO. Therese joins us from Procurator, one of Sweden's leading wholesale companies in areas including protective clothing, hygiene articles and office materials. She has a great deal of experience from financial positions with companies at MTG. Therese Filmersson will take up her post on 1 January 2018, and will join Enzymatica's management team.

  • "We are delighted to recruit Therese - with her considerable experience in expanding companies, she will have a vital input in securing our continued growth", says Fredrik Lindberg, CEO of Enzymatica.
     
  •  "I am looking forward to contributing to Enzymatica's international expansion. With its unique product, the ColdZyme® spray for treating the common cold, Enzymatica has every opportunity to continue its strong growth", says Therese Filmersson.

Therese Filmersson will now be resigning from her position as CFO and Deputy CEO of the Procurator Group, which has sales of around SEK 1.2 billion, with companies in Sweden, Denmark, Norway, Finland and Estonia.
Alongside her responsibilities for Procurator's Finance Department, she also worked in areas such as HR, legal, logistics and strategic IT. Before that, Therese was Finance Director of MTG Internet Retailing, CFO of CDON, Business Area Controller at MTG, CFO/operational Finance Manager at TV Shop Europe AB, Controller/HR Manager at Bravida Syd AB and Controller at ABB Installation, Division South.

For more information, please contact:

Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | E-mail: fredrik.lindberg@enzymatica.com    

About Enzymatica AB
Enzymatica AB is a medical device company that develops and sells medical devices for infection-related diseases. In a short period of time, the company has developed ColdZyme®, a unique mouth spray for the common cold, has launched the product in eight markets and has established it among the top-selling cold products in Swedish kronor terms at Swedish pharmacies. The strategy is to continue to grow by strengthening the company's position in existing markets and expanding into new geographical markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North. For more information, visit:  www.enzymatica.se
Enzymatica's Certified Adviser is Erik Penser Bank.

Phototheresefilmersson


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Enzymatica AB via GlobeNewswire
HUG#2131901
GlobeNewswire
globenewswire.com

Last updated on: 07/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.